OVERVIEW

Module 2 – Disease-Modifying Therapies for ALS: Weighing the Options: Getting Ahead of the ALS Curve Through Early Detection and Intervention is organized by i3 Health.

Dates Available:
May 31, 2024 - May 30, 2025

Statement of Need:
Amyotrophic lateral sclerosis (ALS) is a neurological disorder in which motor neurons degenerate, causing muscles to weaken, twitch, and atrophy. As the disease progresses, affected individuals lose control of voluntary movements; cognitive functions remain intact, so affected individuals are aware of their progressive loss of function and often suffer from anxiety and depression (NIH, 2024). While no treatment exists for reversing motor neuron damage or curing ALS, the last decade has seen significant progress in understanding the genetic and pathophysiological mechanisms of the disease. Currently, there are several FDA-approved disease-modifying therapies with the potential to slow disease progression, prolong survival, and improve quality of life, with numerous more in development (Mead et al, 2022). It is crucial that members of the interdisciplinary care team stay abreast of the latest data on novel disease-modifying therapies in order to optimize outcomes for their patients. In Module 2 of this microlearning series, Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts Hospital and Healey & AMG Center for ALS, and Associate Professor of Physical Medicine and Rehabilitation (PM&R) at Spaulding Rehabilitation Hospital of Harvard Medical School, will share strategies for weighing the options of disease-modifying therapies for ALS.
Learning Objectives:

Upon completion of this activity, participants should be able to:

Assess the clinical utility of novel and existing disease-modifying therapies for individual patients with ALS

ACCREDITATION & CREDITS

JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS
i3 Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 5/29/2025. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development
A maximum of 0.25 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.25 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.25 ANCC contact hours.

Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 0.5 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-24-002-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.

0.5 AMA PRA Category 1 Credit™

0.5 CME / CNE

0.5 CPE

FACULTY

Sabrina Paganoni

MD, PhDPhysical Medicine and Rehabilitation

Timothy John Feyma

Catherine Broome

TARGET AUDIENCE

PhysicianNursingPharmacistPhysician AssistantFamily PhysiciansHealthcare ProfessionalsNeurologistsNursesInternistAdult & Pediatric NeurologySpecialized Nurses in Neurology and RehabilitationNurse AssistantsPsychiatristsPrimary Care PhysiciansNurse Practitioners